Stockhub

Larimar Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

  • curprev 23:4523:45, 15 August 2022 >Paris 503 bytes +503 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. == References and notes == [..."
Retrieved from "https://stockhub.co/research/Larimar_Therapeutics,_Inc."